Publication:
Novel antioxidant N-acetylcysteine amide prevents gp120-and Tat-induced oxidative stress in brain endothelial cells

dc.contributor.authorsPrice, Tulin Otamis; Uras, Fikriye; Banks, William A.; Ercal, Nuran
dc.date.accessioned2022-03-12T17:22:52Z
dc.date.accessioned2026-01-11T10:35:12Z
dc.date.available2022-03-12T17:22:52Z
dc.date.issued2006
dc.description.abstractFree radical production and, consequently, oxidative stress play an important role in the pathogenesis of AIDS and cause damage to lipids, proteins, and DNA. In our previous study, the HIV-1 envelope glycoprotein (gp120) and transregulatory protein (Tat) of HIV-1 have been found to induce oxidative stress in an immortalized endothelial cell line from rat brain capillaries, RBE4 (in vitro model of the blood-brain barrier). Here, we have determined the effects of a novel antioxidant, N-acetylcysteine amide (NACA), on gp120- and Tat-induced oxidative stress. Various oxidative stress parameters, including reduced glutathione (GSH), oxidized glutathione (GSSG), catalase (CAT) activity, and glutathione reductase (GR) activity, as well as malondialdehyde (MDA) levels, were used as measures of oxidative stress. NACA significantly increased the levels of intracellular GSH, CAT, and GR and decreased the levels of MDA in RBE4 cells, showing that oxidatively challenged cells were protected. Gp120- and Tat-induced increases in intracellular reactive oxygen species (ROS) were observed by using the 2',7'-DCF assay; the ROS scavenger, NACA, blocked ROS generation. A well-known apoptosis indicator, caspase-3 activity, was measured and was also found to have been returned to its control levels by NACA. Treatment of RBE4 cells with gp120 and Tat caused an increase in toxicity, as measured by lactate dehydrogenase (LDH) and tetrazolium reduction (MTS) assays. HIV-1 protein-induced toxicity in these cells was blocked by treatment with NACA. These studies show that NACA reverses gp120- and Tat-induced oxidative stress in immortalized endothelial cells. (c) 2006 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.expneurol.2006.03.030
dc.identifier.eissn1090-2430
dc.identifier.issn0014-4886
dc.identifier.pubmed16750528
dc.identifier.urihttps://hdl.handle.net/11424/228453
dc.identifier.wosWOS:000240152100021
dc.language.isoeng
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCE
dc.relation.ispartofEXPERIMENTAL NEUROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectantioxidants
dc.subjectblood-brain barrier
dc.subjectoxidative stress
dc.subjectgp120 protein
dc.subjectTat protein
dc.subjectHIV-1
dc.subjectIN-VITRO MODEL
dc.subjectACETYL CYSTEINE
dc.subjectNERVOUS-SYSTEM
dc.subjectRAT-BRAIN
dc.subjectBARRIER
dc.subjectHIV-1
dc.subjectGLUTATHIONE
dc.subjectMALONDIALDEHYDE
dc.subjectPERMEABILITY
dc.subjectAPOPTOSIS
dc.titleNovel antioxidant N-acetylcysteine amide prevents gp120-and Tat-induced oxidative stress in brain endothelial cells
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage202
oaire.citation.issue1
oaire.citation.startPage193
oaire.citation.titleEXPERIMENTAL NEUROLOGY
oaire.citation.volume201

Files